On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

Shares of vaccine makers, including Moderna (MRNA), BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX), Vaxcyte (PCVX) and GSK (GSK) moved lower at the end of the trading day following reports that ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age group and reducing demand by two-thirds compared to last year.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Will see the 12 quid previous lows, absolutely nothing to warrant buying such a growth-less poorly managed dog index ftse 100 share like gsk. For losers only. My view is that the market is taking ...

Option chain shows key data for GSK's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for GSK.

GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Oct 30 ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year, citing lower-than-expected demand. The company said it's now expecting a low single-digit fall in vaccine sales this ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.